CAS 1374248-77-7

Ubrogepant

Description:

Ubrogepant is a small molecule medication primarily used for the acute treatment of migraine attacks in adults. It belongs to a class of drugs known as CGRP (calcitonin gene-related peptide) receptor antagonists, which work by blocking the action of CGRP, a neuropeptide involved in the pathophysiology of migraines. Ubrogepant is characterized by its oral bioavailability and relatively rapid onset of action, making it effective for migraine relief. Its chemical structure includes specific functional groups that contribute to its pharmacological activity and selectivity for the CGRP receptor. The substance is typically administered in tablet form and is known for its favorable safety profile, with a lower incidence of side effects compared to traditional migraine treatments. Ubrogepant's development represents a significant advancement in migraine management, providing an alternative for patients who may not respond well to other therapies. As with any medication, it is essential for users to consult healthcare professionals for appropriate usage and potential interactions with other drugs.

Formula: C₂₉H₂₆F₃N₅O₃

InChI: InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1

InChI key: InChIKey=DDOOFTLHJSMHLN-ZQHRPCGSSA-N

SMILES: O=C1[C@@]2(C=3C(N1)=NC=CC3)CC=4C(C2)=NC=C(C(N[C@H]5C[C@H]([C@@H](C)N(CC(F)(F)F)C5=O)C6=CC=CC=C6)=O)C4

Synonyms:

• Ubrelvy
• Ubrogepant
• Spiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide, 1′,2′,5,7-tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxo-, (3′S)-
• (3′S)-1′,2′,5,7-Tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxospiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide
• MK 1602

Ubrogepant-d5

CAS: 1374248-77-7

Formula: C₂₉H₂₁D₅F₃N₅O₃

Molecular weight: 554.58

Ref: 4Z-U-018002

Ubrogepant

CAS: 1374248-77-7

Formula: C₂₉H₂₆F₃N₅O₃

Molecular weight: 549.55

Ref: 4Z-U-018001

Ubrogepant

CAS: 1374248-77-7

Ubrogepant

Purity: ≥98%

Molecular weight: 549.54g/mol

Ref: 54-BUP05253

Ubrogepant

CAS: 1374248-77-7

Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, derived from medicinal chemistry research focused on migraine pathophysiology. It functions by selectively binding to the CGRP receptor, thereby blocking the action of CGRP, a neuropeptide implicated in the pathogenesis of migraines. This mechanism disrupts neurogenic inflammation and vasodilation, processes known to contribute to migraine attacks.

Formula: C₂₉H₂₆F₃N₅O₃

Purity: Min. 95%

Molecular weight: 549.54 g/mol

Ref: 3D-FU165699

Ubrogepant

CAS: 1374248-77-7

Ubrogepant (MK-1602) is an antagonist of calcitonin gene-related peptide receptor that can be used in the acute treatment of migraine studies.

Formula: C₂₉H₂₆F₃N₅O₃

Purity: 99.452% - 99.78%

Color and Shape: Solid

Molecular weight: 549.54

Ref: TM-T17194